Construction of a Comprehensive Diagnostic Scoring Model for Prostate Cancer Based on Six Gene-Panel

Abstract

Accumulating evidence indicates that the N6-methyladenosine (m6A) modification plays a critical role in human cancers.Given the current understanding of m6A modification, this process is believed to be dynamically regulated by m6A regulators. Although the discovery of m6A regulators has greatly enhanced our understanding of the mechanism underlying m6A modification in cancers, the function and role of m6A in the context of prostate cancer (PCa) remains unclear.Here, we aimed to establish a comprehensive diagnostic scoring model that can be used to prostate-specific antigen (PSA) screening.To achieve this, we first drew the landscape of m6A regulators and constructed a LASSO-Cox model using 3 risk genes (METTL14, HNRNP2AB1 and YTHDF2). Particularly,METTL14 expression was found to be significantly related to overall survival, tumor T stage and relapse rate, showing that METTL14 has important prognostic value. Furthermore, for the sake of improving the predictive ability, we presented a comprehensive diagnostic scoring model based on 6 gene-panel by combining with genes found in our previous study.In conclusion, our study provides additional clues and insights regarding the treatment and diagnosis of PCa patients. Funding Statement: This work was supported by grants from the National Natural Science Foundation of China (31870928, Project-recepient: Q.L; 81770494, Project-recepient: Q. X.). Declaration of Interests: The authors declare that they have no conflicts of interest.